Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)

CompletedOBSERVATIONAL
Enrollment

1,143

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2015

Conditions
Pneumococcal VaccineStreptococcus Pneumoniae
Interventions
BIOLOGICAL

7-valent vaccine injection

For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.

Trial Locations (1)

816-0801

Yokoyama Children's Clinic, Kasuga

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01521897 - Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) | Biotech Hunter | Biotech Hunter